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Key Points  26 
Question: what is the relationship between schizophrenia related polygenic liability and 27 
the occurrence and level of mood-incongruence of psychotic symptoms in bipolar 28 
disorder (BD)?  29 
Findings: in this case-control study including 4436 BD cases, 4976 schizophrenia cases 30 
and 9012 controls, there was an exposure-response gradient of polygenic risk: 31 
Schizophrenia > BD with prominent mood-incongruent psychotic features > BD with 32 
mood-congruent psychotic features > BD with no psychosis, all differential associations 33 
were statistically-significant.  34 
Meaning: A gradient of genetic liability across schizophrenia and bipolar disorder, 35 
indexed by the occurrence of psychosis and level of mood-incongruence has been 36 
shown for the first time.  37 
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Abstract  38 
Importance  39 
Bipolar disorder (BD) overlaps schizophrenia in its clinical presentation and genetic 40 
liability. Alternative approaches to patient stratification beyond current diagnostic 41 
categories are needed to understand the underlying disease processes/mechanisms. 42 
Objectives 43 
To investigate the relationship between common-variant liability for schizophrenia, 44 
indexed by polygenic risk scores (PRS) and psychotic presentations of BD, using clinical 45 
descriptions which consider both occurrence and level of mood-incongruent psychotic 46 
features. 47 
Design 48 
Case-control design: using multinomial logistic regression, to estimate differential 49 
associations of PRS across categories of cases and controls. 50 
Settings & Participants  51 
4399 BDcases, mean [sd] age-at-interview 46[12] years, of which 2966 were woman 52 
(67%) from the BD Research Network (BDRN) were included in the final analyses, with 53 
data for 4976 schizophrenia cases and 9012 controls from the Type-1 diabetes genetics 54 
consortium and Generation Scotland included for comparison. 55 
Exposure 56 
Standardised PRS, calculated using alleles with an association p-value threshold < 0.05 57 
in the second Psychiatric Genomics Consortium genome-wide association study of 58 
schizophrenia, adjusted for the first 10 population principal components and 59 
genotyping-platform.  60 
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Main outcome measure 61 
Multinomial logit models estimated PRS associations with BD stratified by (1) Research 62 
Diagnostic Criteria (RDC) BD subtypes (2) Lifetime occurrence of psychosis.(3) Lifetime 63 
mood-incongruent psychotic features and (4) ordinal logistic regression examined PRS 64 
associations across levels of mood-incongruence. Ratings were derived from the 65 
Schedule for Clinical Assessment in Neuropsychiatry interview (SCAN) and the Bipolar 66 
Affective Disorder Dimension Scale (BADDS).  67 
Results  68 
Across clinical phenotypes, there was an exposure-response gradient with the strongest 69 
PRS association for schizophrenia (RR=1.94, (95% C.I. 1.86, 2.01)), then schizoaffective 70 
BD (RR=1.37, (95% C.I. 1.22, 1.54)), BD I (RR= 1.30, (95% C.I. 1.24, 1.36)) and BD II 71 
(RR=1.04, (95% C.I. 0.97, 1.11)). Within BD cases, there was an effect gradient, indexed 72 
by the nature of psychosis, with prominent mood-incongruent psychotic features having 73 
the strongest association (RR=1.46, (95% C.I. 1.36, 1.57)), followed by mood-congruent 74 
psychosis (RR= 1.24, (95% C.I. 1.17, 1.33)) and lastly, BD cases with no history of 75 
psychosis (RR=1.09, (95% C.I. 1.04, 1.15)).  76 
Conclusion 77 
We show for the first time a polygenic-risk gradient, across schizophrenia and bipolar 78 
disorder, indexed by the occurrence and level of mood-incongruent psychotic 79 
symptoms. 80 
81 
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Introduction  82 
Although classified as a discrete diagnostic category
1-3
, bipolar disorder (BD) overlaps 83 
considerably with schizophrenia (SCZ) in both its clinical presentation 
4-13
 and genetic 84 
liability 
14-22
. BD is a phenomenologically heterogeneous construct and within the 85 
diagnostic category, individuals may have quite different symptom profiles. It has been 86 
proposed, that this clinical heterogeneity indicates underlying aetiological 87 
heterogeneity and the degree of clinical similarity between BD and SCZ reflects, 88 
overlapping alleles which selectively influence specific, shared clinical characteristics, 89 
rather than the global risk for the disorders 
23-25
. 90 
Delusions and hallucinations are common in BD 
26,27
 with around one third of all 91 
psychotic features judged to be mood-incongruent 
28,29
. Mood-incongruent psychotic 92 
features, are associated with poorer prognosis, poor lithium-response and are 93 
qualitatively similar to the prototypic symptoms of SCZ 
30-32
, suggesting that BD with 94 
psychosis and particularly mood-incongruent psychotic features, may specify a 95 
subgroup/stratum with stronger aetiological links to SCZ. Stratified linkage and 96 
candidate-gene studies of BD associations with chromosomal regions and genes 97 
implicated in SCZ, show stronger effects in psychosis and mood-incongruent 98 
subsamples 
33-36
 providing some support for this causal heterogeneity hypothesis, 99 
however lack of consistency in earlier linkage and candidate-gene studies renders the 100 
overall support weak.  101 
Recently, genome-wide association studies (GWAS) have found a substantial polygenic 102 
component to both BD and SCZ risk, with a large proportion of their genetic variance 103 
explained by common alleles, partially shared across the two disorders 
20
. Polygenic-104 
risk can be calculated for individuals, with a single summary measure: the polygenic 105 
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risk score (PRS), which allows us to examine the genetic basis of symptom domains, 106 
within and across the two disorders 
37-39
 with greater power than the historical linkage 107 
and candidate-gene approaches. PRS-SCZ differentiate BD from controls 
20,40
 and there 108 
are differential associations across subtypes with schizoaffective bipolar disorder 109 
(SABD) (intermediate subtype, characterised by admixture of SCZ and BD symptoms) 110 
having a relatively larger burden of SCZ risk, compared to other BD subtypes 
15,41
. To 111 
date, lack of power in well phenotyped samples has hindered fine-scale examination of 112 
the relationship between SCZ polygenic-risk and psychotic symptoms in BD.  113 
We aimed to examine the relationship between polygenic liability for SCZ and psychotic 114 
presentations of BD using PRS generated from the most powerful SCZ-GWAS discovery 115 
set available, currently 
21
. Measures relevant to the occurrence and nature of psychotic 116 
symptoms were considered. We hypothesised BD with psychosis would be associated 117 
with higher polygenic-risk for SCZ and this association would be stronger when mood-118 
incongruent psychotic features were present, given their phenotypic similarity to the 119 
psychotic symptoms of prototypic SCZ. 120 
Methods  121 
Sample Ascertainment  122 
Bipolar Disorder sample 123 
4436 cases of BD with deep phenotypic information, European ancestry, domicile in the 124 
UK, collected between 2000 - 2013 were available via the UK BD Research Network 125 
(BDRN) using recruitment methods reported previously 
15,42,43
. The sample has 1399 126 
cases not included in prior BDRN publications 
15,41
. All participants were assessed using 127 
a consistent protocol which included the Schedule for Clinical Assessment in 128 
Neuropsychiatry interview (SCAN) 
44
 administered by trained research psychologists 129 
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and psychiatrists, with very good to excellent inter-rater reliability for all domains of 130 
psychopathology 
45
. Using information from the SCAN and casenote review, the 131 
Operational Criteria Checklist (OPCRIT) 
46
 was completed. Research Diagnostic Criteria 132 
(RDC) 
3
diagnoses, which differentiate individuals on the basis of the their pattern of 133 
mood and psychotic symptoms better 
41
 than either DSM 
2
 or ICD–10
1
, were made using 134 
the consensus lifetime best-estimate method, informed by all available information
47
. 135 
Schizophrenia sample  136 
To allow comparison of BD with SCZ, we included a subset (N=4976) of the CLOZUK 137 
sample, collected via the Zapronex
®
 Treatment Access System as detailed in a previous 138 
report
48
, All were prescribed clozapine for treatment resistant SCZ (TRS) and are 139 
independent of, and unrelated (pi-hat <0.2) to individuals in the discovery GWAS
21
. In 140 
principle, TRS may carry higher polygenic-risk burden, however PRS in CLOZUK are 141 
similar to the other SCZ samples used by the Psychiatric Genomics Consortium
21
.  142 
Control Samples  143 
The controls came from two UK sources: the Type-1 diabetes genetics consortium 144 
(TIDGC) (n = 2,532) are unscreened controls, recruited through the 1958 birth-cohort 145 
49
 and the other is a subsample of the Generation Scotland (n = 6,480) study, screened 146 
for psychiatric disorders 
50
. Controls are unrelated (pi-hat < 0.2) to individuals in the 147 
PGC-SCZ discovery set, and were matched ancestrally to our case datasets 
48
. 148 
All samples have appropriate ethics approvals.  149 
Genotyping, quality control (QC), phasing and imputation  150 
Bipolar cases 151 
Genotypic data for the BD cases were processed in 3 batches, each on a different 152 
platform. To mitigate against potential bias from batch effects
51
, stringent QC was 153 
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performed on each platform separately prior to merging. Single nucleotide 154 
polymorphisms (SNPs) were excluded if the call rate was < 98%, MAF was < 0.01 or 155 
they deviated from HWE at p < 1x10
-6
. Individuals were excluded if they had minimal or 156 
excessive autosomal homozygosity (|F|>0.1), high pairwise relatedness (pi-hat > 0.2) 157 
or mismatch between recorded and genotypic sex. Following QC, the data for each 158 
platform were phased using SHAPEIT 
52
 and imputed with IMPUTE2 
53
, using the 1000 159 
Genomes reference panel (Phase3, 2014). Imputed data were converted into the most 160 
probable genotypes (probability >0.9) and merged on shared SNPs. 4399 BD cases 161 
remained after QC.  162 
CLOZUK cases and Controls 163 
The CLOZUK and control samples had been though strict QC separately, before being 164 
phased and imputed simultaneously as part of a larger SCZ study 
48
. 165 
Merging BD, CLOZUK and control imputed genotypic datasets 166 
After excluding SNPs with stand ambiguity; BD, CLOZUK and control samples were 167 
merged and the imputed markers underwent a second QC filter
51
, excluding SNPs with; 168 
missingness in >5% of individuals, (INFO) <0.8, MAF <0.01 or deviation from HWE at p 169 
< 1x10
-6 
 . 170 
Principal Component Analysis  171 
To adjust for potential confounding from population structure, we performed PCA using 172 
PLINK v1.9, after LD pruning and frequency filtering the SNPs from the merged sample, 173 
keeping the eigenvectors for the first 10 principal components (PCs) to use as 174 
covariates in the association analysis. 175 
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Polygenic Risk Scores (PRS) 176 
We generated PRS
20
, using the 2014 PGC-SCZ meta-analysis as our discovery set
21
 177 
calculated for each individual, based on a set of alleles with association p-values < 0.05. 178 
This decision was informed by the PGC leave one-cohort-out PRS analyses, for all SNP 179 
selection p-value thresholds, which found the median and mode of the cut-off = 0.05. 180 
This represents the association that best optimises the balance of false and true risk 181 
alleles, at the current discovery sample size 
21
. The most informative and independent 182 
markers were selected to minimise statistical noise where possible, using p-value 183 
informed clumping, at r
2
 <0.2 with 1MB windows and by excluding the extended MHC 184 
(Chr6: position 25-35MB) because of its complex LD structure . 185 
Outcome measure of lifetime psychosis & mood incongruence  186 
Subtypes of BD 187 
RDC subtypes were used as categorical outcomes in case-control analyses. The RDC 
3
 188 
and Diagnostic and Statistical Manual of Mental Disorders (DSM) 
2
, though not the ICD-189 
10 Classification of Mental and Behavioural Disorder (ICD-10) 
1
, subdivides BD into 190 
bipolar I disorder (BD I) and bipolar II disorder (BD II) depending on the nature of the 191 
mood states; mania in (BP I) and hypomania in (BP II). All classification systems 192 
recognise SABD. Psychotic symptoms are most prominent in SABD, then BD I, and least 193 
prominent in BD II 
54,55
. 194 
The Bipolar Affective Disorder Dimension Scale  195 
Outcome measures were generated from The Bipolar Affective Disorder Scale (BADDS) 196 
Psychosis (P) and mood-incongruence (I) subscales, which provide an ordered (not 197 
necessarily linear) measure of lifetime symptom domain severity
56
. An inter-rater 198 
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reliability exercise for this sample demonstrates excellent interclass correlation: (P) 199 
0.91 and (I) 0.89. 200 
1) A binary categorical outcome measure for lifetime occurrence of psychosis defined as 201 
an unambiguous episode of positive and/or disorganised psychotic symptoms, 202 
generated by dichotomising the (P) domain scale at a score > 9 
56
. 203 
2) A binary categorical outcome measure for lifetime occurrence of predominant mood-204 
incongruent psychotic features (high v low prominence of mood-incongruence), 205 
generated by dichotomising the (I) domain scale at a score >19.  206 
3) An ordinal measure of mood-incongruent psychotic features which assesses the 207 
overall balance between mood-congruent and mood-incongruent psychosis across the 208 
lifetime, rated using all available information according to BDRN protocol (E 209 
supplement : Note 1)  210 
Statistical Analysis  211 
A multinomial logit model (MNLM) was used to estimate differential associations of 212 
standardised PRS, adjusted for the first 10 PCs and genotyping-platform, across 213 
categories of cases and controls. We report the estimated coefficients transformed to 214 
relative risk-ratios (RR), defined as the exponentiated regression coefficient. PRS 215 
association across levels of mood-incongruent psychotic features using ordinal logistic 216 
regression was also estimated. To examine whether SABD subtypes were driving 217 
observed PRS associations with mood-incongruent psychotic features, we did a 218 
sensitivity analysis excluding SABD cases. Post-estimation predicted probabilities were 219 
plotted to aid interpretation of the PRS associations across RDC subtypes of BD 
57
. To 220 
correct for multiple comparisons of PRS associations across different phenotypic strata 221 
within each model, bootstrapped standard errors and 95% confidence intervals were 222 
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generated, as an approximation to exact permutation methods 
58
(supplementary E - 223 
Note 2). Possible family-wise type-1 error proliferation was controlled for using the 224 
Bonferroni Method, calculated by multiplying the bootstrapped p-values by four 
59
. 225 
Post-hoc analyses used a MNLM case-control design to examine differential associations 226 
across composite phenotypic categories defined by subtype BDI and BD II stratified by 227 
psychosis status and a complementary logistic regression analyses comparing the effect 228 
of PRS on lifetime occurrence of psychosis, across BD I and BD II subtypes. To examine 229 
the distribution of RDC defined cases across levels of PRS, we converted PRS to deciles 230 
and generated a stacked bar-chart (SCZ (CLOZUK), SABD, BD I, BD II), by decile.  231 
Analyses were performed using PLINK v1.9 
60
 or STATA (Stata Statistical Software: 232 
Release 14. College Station, TX: Stata Corp, LP). 233 
Results  234 
Sample description, Genotyping and quality control  235 
After merging BD, CLOZUK and control imputed-genotyped samples and further QC, 236 
18,387 cases and controls (E-supplementary Table 1) with 3,451,354 SNPs with INFO 237 
score > 0.8 and MAF >1% were available for analysis. Within the BD sample 52% (N = 238 
2296) of cases endorsed lifetime occurrence of definite psychosis, with <1% 239 
missingness in this variable (N=25). Of the BD cases with definite psychosis, 43% (N= 240 
981) were classed as having high lifetime mood-incongruent psychotic features. There 241 
was a 9% (N=214) missingness rate for the mood-incongruence variable, within the BD 242 
cases with psychosis. 243 
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 Case Control PRS associations  244 
As expected (Table 1 Section A), PRS discriminated CLOZUK from controls. PRS in those 245 
with a diagnosis of SABD or BD I, but not BD II, were significantly higher than controls. 246 
PRS associations within cases 247 
PRS discriminated SCZ from all BD subtypes (Table 2). Within BD, PRS discriminates BD 248 
II from both BD I and SABD (Figure 1). The percentage of CLOZUK cases increased 249 
monotonically with increasing decile PRS, while the percentage of bipolar subtypes 250 
decreased (Figure 2). 251 
PRS associations with psychotic BD  252 
Compared to controls, the PRS were higher in BD, regardless of whether there was  a 253 
history of psychosis (Table 1, Section B, Figure 2). However, PRS were significantly 254 
higher in BD with psychosis, compared to BD without psychosis (Table 1, Section B, 255 
figure 3). Within BD cases, PRS discriminated those with and without psychosis 256 
(RR=1.25, 95% bootstrapped adjusted p-value < 001, C.I. (1.16, 1.33)). 257 
Post hoc analyses showed the association between PRS and psychosis was present in BD 258 
I (OR = 1.21, 95% C.I. 1.10, 1.32) but were not statistically significant in BD II (OR = 259 
0.98, 95% C.I. 0.80, 1.18). Composite subgroup defined as BD I with psychosis - had 260 
higher PRS compared to controls (RR = 1.38, 95% C.I. 1.31, 1.46) this association was 261 
significantly stronger than that of the composite BD I/no psychosis (RR= 1.16, 95% C.I. 262 
1.08, 1.25). Within BD II, there was no differential association across subgroups defined 263 
by presence/absence of psychosis as compared to controls (supplementary-E: Table-1).  264 
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PRS associations with mood-incongruent psychotic features  265 
Psychotic BD characterised by high mood-incongruence has a higher SCZ polygenic risk 266 
burden than controls, with a one standard-deviation increase in PRS increasing the RR 267 
of being in the high mood-incongruence category by 46% (RR= 1.46, bootstrapped, 268 
95% C.I. 1.36, 1.57) (Figure 3, Table 1 Section C). Although the association was 269 
significantly weaker than for the high mood-incongruent group, schizophrenia risk-270 
alleles were enriched in those with low mood-incongruence compared with controls 271 
(RR= 1.24, bootstrapped 95% C.I. (1.17, 1.33). Sensitivity analysis excluding the SABD 272 
group from analyses found comparable results (Table 1: Section D). Finally, a within-273 
BD-case analysis, measuring mood-incongruence on an ordinal scale found the odds of 274 
having higher levels of mood-incongruence, increased with increasing PRS ( OR=1.17, 275 
(bootstrapped p-value < .001, 95% C.I. 1.08 - 1.27)). Analyses excluding the SABD 276 
sample found comparable results (OR=1.20, bootstrapped p-value < .001, 95% C.I. 277 
1.09, 1.32).  278 
Discussion  279 
Main Findings 280 
Higher PRS-SCZ in BD 
20,61
 is well established. Here, we replicate and extend this 281 
observation, demonstrating a gradient of PRS associations across SCZ and BD subtypes 282 
(CLOZUK > SABD > BD I with psychosis > BD I without psychosis > BD II). We also 283 
show BD cases with psychosis carry a higher burden of SCZ risk-alleles, compared to BD 284 
without a history of psychosis. Furthermore, individuals with psychotic BD 285 
characterised by prominent mood-incongruent psychotic features, carry the highest 286 
burden of schizophrenia risk-alleles. There is a clear exposure-response gradient, with 287 
increasing PRS associated with psychotic BD and increasing mood-incongruence 288 
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(mood-incongruent > mood-congruent > no psychosis), supporting our hypothesis that 289 
mood-incongruence indexes phenotypic features linked to SCZ liability.  290 
Previously published work examining PRS for SCZ across BD, stratified by psychosis, did 291 
not find significant discrimination 
41,62
 although a trend was observed, consistent with 292 
the findings presented here. The most likely explanations for the enhanced signal in the 293 
current analysis are: PRS were constructed using alleles derived from a larger SCZ-294 
GWAS discovery set which reduces measurement error plus improved power from both 295 
this and the larger BD sample 
63
. This group has shown
41
, PRS-SCZ significantly 296 
differentiate SABD from non-SABD subtypes, while finding no statistically significant 297 
differential between BD stratified by psychosis, suggesting it is the nature of the 298 
psychotic symptoms rather than their presence which better indexes liability shared 299 
with SCZ. The current analysis supports this proposition that it is the level of mood-300 
incongruence rather than the presence of psychosis per se which better specifies a 301 
shared biologically-validated dimensional trait, captured, but with less precision by the 302 
SABD diagnostic category.  303 
Psychosis and mood-incongruent psychotic features are known to be correlated to 304 
poorer prognosis and treatment response
30-32
 It is possible the trans-diagnostic 305 
exposure-response gradient for PRS with the occurrence and nature of psychotic 306 
symptoms presented here, could be the result of a general psychopathological factor 307 
cutting across psychiatric disorders which influences the severity of psychopathology 308 
generally, as well as, or rather than a psychosis-specific domain and that PRS derived 309 
from SCZ GWAS may be indexing a general liability for psychopathology severity (at 310 
least in part)
64
 rather than a (SCZ) disease specific liability.  311 
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Implications  312 
Our study supports the hypothesis that within BD, positive and disorganized psychotic 313 
symptoms, and in particular mood-incongruent psychotic features, represent a 314 
dimensionally defined stratum with underpinning biological validity. These features are 315 
not only phenotypically similar to those observed in prototypal schizophrenia but also 316 
index a greater shared genetic aetiology suggesting they share more pathophysiology 
65
. 317 
It is notable that in those diagnosed with BD I with no history of psychosis, the 318 
association with schizophrenia liability was weaker but still on average higher than in 319 
the control group, while in the BD II subsample there was no overlap with SCZ liability. 320 
We are not suggesting psychotic features are the best or only index of shared 321 
pathophysiology, but having established stronger genetic links between the risk for SCZ 322 
and BD characterised by the occurrence of psychosis and level of mood-incongruence, 323 
we now have a basis to refine this signal. These findings represent a step towards the 324 
goal of reconceptualising phenotypic definitions using richer clinical signatures, 325 
measured across quantitative/qualitative domains including, symptom loadings and 326 
biomarker expression, outlined in the rationale for the Research Domain Criteria 327 
(RDoC) 
66,67
 and the road map for mental health research (ROAMER) 
68
 projects. It is 328 
probable however a multidimensional stratification process will harness the observed 329 
clinical heterogeneity better and define more precise patient-strata/subgroups in closer 330 
alignment with the underlying pathophysiology 
68-70
 331 
Methodological considerations  332 
The phenotypic ratings used in the current analyses are based on both SCAN interviews 333 
and case-note review by raters with excellent inter-rater reliability, which is expected to 334 
minimise rates of missing data and reduce the likelihood of phenotypic 335 
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misclassification
71
. Our psychosis phenotypes are broadly defined and likely to 336 
represent imperfect measurements of a continuously distributed phenotype
72
, imposing 337 
categorical constraints as we have done may reduce power. We generated PRS using a 338 
single discovery set p-value threshold < 0.05 and dealt with multiple comparisons, 339 
across different phenotypic categories/strata using bootstrap re-sampling approaches 340 
within each of our 4 independent analyses, adjusting for family-wise type-1 error 341 
proliferation using Bonferroni’s correction. We have mitigated against potential 342 
confounding due to population stratification and potential batch effects across cases 343 
and controls, by partialling out the first 10 PCs and genotyping platforms from the PRS. 344 
The PRS were generated using most probable genotypes which can potentially reduce 345 
power due to a small (non-differential) loss of information at some markers making our 346 
results conservative, but the conclusions are unlikely to change. Finally, we have only 347 
examined the effect of common variants, as rare variants are not captured by current 348 
GWAS.  349 
Conclusions  350 
We show for the first time a gradient of polygenic liability across schizophrenia and 351 
bipolar disorder, indexed by the occurrence and level of mood-incongruence of positive 352 
and disorganised psychotic symptoms. This highlights the usefulness of genetic data to 353 
dissect clinical heterogeneity within and across disorders, and suggests further research 354 
could potentially aid in defining patient stratifiers with improved biological 355 
precision/validity, moving us tentatively towards precision medicine in psychiatry.  356 
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Table 1:Differential Association of PRS across variously defined BD strata 
(controls as comparator category) 
 N 
(subsample)  
RR Bootstrapped 
p-value 
Bonferroni 
Corrected p-value  
Bootstrapped 95% 
confidence intervals 
CLOZUK  4,976 1.94 < .001 < .001 1.86, 2.01 
  A) Bipolar Disorder cases stratified by RDC defined subtypes 
SABD 356 1.37 < .001 < .001 1.22, 1.54 
BD I 2,775 1.30 < .001 < .001 1.24. 1.36 
BD II 1,268 1.04 0.26 0.26 0.97, 1.11 
  B) Bipolar Disorder cases stratified by lifetime occurrence of 
psychosis 
No LEP 2,079 1.09 0.001 0.004 1.04, 1.15 
LEP 2,296 1.36 < .001 < .001 1.29, 1.43 
  C) Psychotic Bipolar Disorder cases stratified by level of mood 
incongruence 
Low LMI 1,126 1.24 < .001 < .001 1.17, 1.33 
High LMI 981 1.46 < .001 < .001 1.36, 1.57 
  D) Sensitivity Analysis: Psychotic Bipolar Disorder cases 
stratified by levels of mood incongruence (excluding SABD cases)  
Low LMI  1,068 1.25 < .001 < .001 1.16, 1.33 
High LMI 699 1.49 < .001 < .001 1.37, 1.62 
 
CLOZUK – Treatment resistant Schizophrenia, treated with clozapine, BD I - RDC bipolar disorder subtype I, BD II - RDC 
bipolar disorder type II, SABD-RDC bipolar schizoaffective disorder, LEP – lifetime ever occurrence of psychotic symptoms, 
LMI – lifetime pattern of low/high mood incongruent psychotic features RR – relative risk ratio PRS adjusted for 1
st
 10 PCs 
and genotyping platform 
 
Table 2: PRS-SCZ associations among cases  
 RR Bootstrapped 
p-value  
 Bonferroni 
corrected p-value 
Bootstrapped 
95% C.I. 
SABD compared toTRS 0.71 < .001 < .001 0.63, 0.80 
BD I compared to TRS 0.67 < .001 < .001 0.64, 0.71 
BD II compared to TRS  0.54 < .001 < .001 0.50, 0.57 
SABD compared to BD II 1.32 < .001 < .001 1.16, 1.50 
BP I compared to BD II 1.25 < .001 < .001 1.16, 1.35 
SABD compared to BD I 1.05 0.41 0.41 0.93, 1.18 
 
TRS - treatment resistant schizophrenia, treated with clozapine, BDI - RDC bipolar disorder subtype I, BD II - RDC bipolar 
disorder type II, SABD-RDC bipolar schizoaffective disorder, RR – relative risk ratio PRS adjusted for 1
st
 10 PCs and 
genotyping platform 95% bootstrapped C.I. - 95% confidence intervals.  
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